Peptide Knowledge Base · Immune

Thymalin: what it is, what the evidence says, and its real status

A thymus-derived 'bioregulator' from the Khavinson canon, pitched for immune and aging support.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does Thymalin work?

A thymus-derived peptide preparation proposed to restore immune balance, in the Khavinson 'bioregulator' tradition.

What it does — and what it does not do

What it does: Claimed in Russian-origin work to support immune function in aging.

What it does not do: It is not independently validated.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

Russian-origin claims; limited independent replication

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Independent replication is limited; outcomes unconfirmed.

WADA status: Not prohibited.

How it is taken

No established independent clinical dosing; research-stage.

Who should not take it

Not characterized in independent practice; no established safety profile.

Sources

Khavinson thymic-peptide literature (limited independent replication)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.